Enforcement news, scam patterns, China supply-chain reporting, and quality-control guidance for the research peptide grey market.
The FDA revised Import Alert 66-80 on October 9, 2026, adding orforglipron entries, expanding product codes, and detailing records manufacturers may need to show CGMP compliance. The update concerns imported GLP-1 active pharmaceutical ingredients and detention without physical examination; it does not approve unapproved GLP-1 products or create a consumer purchasing pathway.
A July 2026 DOJ resolution involving Alibaba and a Utah indictment illustrate how opaque peptide supply chains, relabeling, and marketplace systems can expose consumers to unverified products.
The FDA added Kybella warning information after reviewing adverse-event reports involving deoxycholic acid injections outside the approved under-chin area. The agency identified 129 non-submental cases and 117 unresolved nodules or masses, clarifying the safety boundary between FDA-approved submental treatment and broader injection-lipolysis claims.
FDA’s September 21, 2026 revision to Import Alert 66-80 adds specified orforglipron API and intermediate entries to the Green List framework, updates product coding and details manufacturer documentation FDA may evaluate. The 21% figure among 48 assessed sites remains important context from the ongoing GLP-1 API compliance effort.
The FDA’s February 4, 2026 alert on unapproved GLP-1 drugs brings several risks into one regulatory warning: more than 1,720 reported adverse events involving compounded semaglutide and tirzepatide, fraudulent pharmacy labels, dosing errors, questionable salt forms, shipping-temperature failures, and illegal retatrutide marketing. Here is what the alert means and how it changes the quality conversation around unapproved weight-loss injections.
The FDA added three more products to its continuing yellow oleander safety alert on September 17, 2026. Laboratory testing found toxic yellow oleander in two Niwali products and Easy Forte Natural Fiber, reinforcing concerns that botanical weight-loss products may be substituted, mislabeled, or contaminated. The update is materially different from the agency’s August warning because it expands the investigation beyond products explicitly labeled as tejocote root and shows that the problem is continuing across multiple product formats and selling channels.
A 2026 federal temporary-scheduling action places mitragynine pseudoindoxyl, MGM-15, and MGM-16 under heightened Controlled Substances Act scrutiny. This analysis explains the order’s legal scope, why it distinguishes specified manufactured compounds from traditional botanical kratom, and what it means for research, laboratory analysis, and consumer-product transparency.
A federal guilty plea announced September 14, 2026 provides a documented look inside a grey-market anabolic steroid supply chain. DOJ described multi-kilogram steroid powders from China, subsequent production of injectable and oral products, private-label distribution, packaging materials, ledgers, cash, and firearms. The case illustrates why professional-looking bodybuilding products may still lack verifiable identity, potency, sterility, traceability, and regulated manufacturing controls.
A peer-reviewed August 2026 grey market semaglutide study tested whether adults could correctly handle and use peptide semaglutide obtained without a prescription. Participants completed only 44% of required steps, with errors capable of causing incorrect dosing, needle sticks and infections. The findings add a human-factors warning to FDA concerns about unapproved GLP-1 products, fraudulent labels and dosing errors.
A peer-reviewed study published July 30, 2026 found that tested compounded and follow-on semaglutide and liraglutide products contained impurity profiles different from their originator products. The findings add a scientific layer to discussion of compounded GLP-1 quality: the issue is not only whether a vial contains the labeled peptide, but whether manufacturing and storage create altered peptide forms that may affect stability or immune recognition.
